$1.49
0.00% day before yesterday
Nasdaq, Dec 27, 10:15 pm CET
ISIN
US19249H1032
Symbol
CHRS
Sector
Industry

Coherus BioSciences, Inc. Stock price

$1.49
+0.23 18.25% 1M
-0.21 12.35% 6M
-1.84 55.26% YTD
-1.20 44.61% 1Y
-16.19 91.57% 3Y
-16.72 91.82% 5Y
-14.87 90.89% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.00 0.00%
ISIN
US19249H1032
Symbol
CHRS
Sector
Industry

Key metrics

Market capitalization $171.67m
Enterprise Value $373.46m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.23
P/S ratio (TTM) P/S ratio 0.56
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 44.19%
Revenue (TTM) Revenue $304.34m
EBIT (operating result TTM) EBIT $-130.98m
Free Cash Flow (TTM) Free Cash Flow $-62.02m
Cash position $97.69m
EPS (TTM) EPS $-0.10
P/E forward 4.22
P/S forward 0.67
EV/Sales forward 1.46
Short interest 31.11%
Show more

Is Coherus BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Coherus BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Coherus BioSciences, Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Coherus BioSciences, Inc. forecast:

Buy
100%

Financial data from Coherus BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
304 304
44% 44%
100%
- Direct Costs 174 174
86% 86%
57%
131 131
11% 11%
43%
- Selling and Administrative Expenses 163 163
14% 14%
54%
- Research and Development Expense 93 93
10% 10%
31%
-126 -126
29% 29%
-41%
- Depreciation and Amortization 5.31 5.31
17% 17%
2%
EBIT (Operating Income) EBIT -131 -131
28% 28%
-43%
Net Profit -0.45 -0.45
100% 100%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Coherus BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coherus BioSciences, Inc. Stock News

Neutral
GlobeNewsWire
11 days ago
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -
Positive
Seeking Alpha
12 days ago
Coherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS holds $97.7 million in cash, $36.6 million in term loans, and $227.9 million in convertible notes, with $70.8 million in net revenues. CHRS is divesting their Udenyca franchise for $483.4 million, wit...
Neutral
GlobeNewsWire
about one month ago
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET.
More Coherus BioSciences, Inc. News

Company Profile

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Head office United States
CEO Denny Lanfear
Employees 306
Founded 2010
Website www.coherus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today